DNLI logo

DNLI

Denali Therapeutics Inc.

$15.27
-$0.38(-2.43%)
42
Overall
--
Value
40
Tech
44
Quality
Market Cap
$2.27B
Volume
1.89M
52W Range
$10.57 - $33.33
Target Price
$32.20
Order:

Income Statement

MetricTrendChart
2018
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$129.2M$335.6M$48.7M$105.1M$330.5M--
Total Revenue
$129.2M$335.7M$48.7M$108.5M$330.5M--
GROSS PROFIT
Gross Profit
$129.2M$335.7M$48.7M$108.5M$330.5M--
OPERATING EXPENSES
Operating Expenses
$-175.5M$272.9M$344.4M$449.2M$527.2M$501.9M
Research & Development
$143.2M$212.6M$265.4M$358.7M$423.9M$396.4M
Research Expense
$143.2M$212.6M$265.4M$358.7M$423.9M$396.4M
Selling, General & Administrative
$32.3M$60.3M$79.1M$90.5M$103.4M$105.4M
General & Administrative Expenses
$32.3M$60.3M$79.1M$90.5M$103.4M$105.4M
Salaries & Wages
$-18.8M----------
Depreciation & Amortization
$-7.4M$8.5M$8.6M$10.4M$16.7M$7.8M
Depreciation & Amortization
$-7.4M$8.5M$8.6M------
Amortization
----------$1.2M
Other Operating Expenses
$-1.5M$-3.0M$-4.7M------
OPERATING INCOME
Operating income
$-46.4M$62.7M$-295.8M$-340.7M$-196.7M$-487.3M
EBITDA
$-28.8M$71.2M$-287.2M$-315.6M$-180.0M$-492.9M
NON-OPERATING ITEMS
Intinc
$10.1M------$51.5M$64.6M
Net Non-Operating Interest Income/Expense
$10.1M----$-14.8M$51.5M$64.6M
Gain on Sale of Securities
--$100.0K--------
Other Income/Expense
--$-9.3M$-4.6M$-18.2M$-51.5M--
Other Special Charges
--$9.3M$4.6M$18.2M$51.5M--
PRE-TAX INCOME
EBIT
$-36.2M$62.7M$-295.8M$-326.0M$-196.7M$-501.9M
Pre-Tax Income
$-36.2M$72.0M$-291.2M$-326.0M$-145.2M$-422.7M
INCOME TAX
Tax Provision
--$823.0K$-575.0K$21.0K$30.0K$68.0K
NET INCOME
Net Income
$-36.2M$71.1M$-290.6M$-326.0M$-145.2M$-422.8M
Net Income (Continuing Operations)
$-36.2M$71.1M$-290.6M$-326.0M$-145.2M$-422.8M
Net Income (Discontinued Operations)
$-36.2M$71.1M$-290.6M$-326.0M$-145.2M$-422.8M
Net Income (Common Stockholders)
$-36.2M$71.1M$-290.6M$-326.0M$-145.2M$-422.8M
TOTALS
Total Expenses
$-175.5M$272.9M$344.4M$449.2M$527.2M$501.9M
SHARE & EPS DATA
Average Shares Outstanding
$92.6M$109.0M$121.5M$125.5M$137.4M$164.5M
Average Shares Outstanding (Diluted)
$97.7M$112.7M$121.5M$125.5M$137.4M$164.5M
Shares Outstanding
$190.6M$121.0M$122.8M$136.7M$139.2M$145.2M
Basic EPS
$0.82$0.65$-2.39$-2.6$-1.06$-2.57
Basic EPS (Continuing Operations)
--$0.65$-2.39$-2.6$-1.06$-2.57
Diluted EPS
$-0.39$0.63$-2.39$-2.6$-1.06$-2.57
Diluted EPS (Continuing Operations)
--$0.63$-2.39$-2.6$-1.06$-2.57
OTHER METRICS
Gains Loss On Disposal Of Discontinued Operations
----------$14.5M
Net Income Discontinuous Operations
----------$14.5M
Other Gand A
$32.3M$60.3M$79.1M$90.5M$103.4M$105.4M
Rent And Landing Fees
$32.3M----------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2DNLI$15.27-2.4%1.89M
3
4
5
6

Get Denali Therapeutics Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.